RIO trial and new signals lift cure momentum

Global cure-related trials now total 21,254, while Wire activity continues to accelerate: 30 new Wire signals arrived in the last 24h and only 1 new Cure research item was logged. The most consequential development cited is the RIO phase II randomized controlled trial reporting secondary and exploratory outcomes of broadly neutralizing antibody therapy (3BNC11) in adult males living with HIV undergoing analytical treatment interruption. This matters because it adds clinical evidence to a strategy aimed at controlling HIV without ongoing therapy, directly informing how cure-relevant regimens may be refined and combined. Restraint is warranted—these are secondary and exploratory outcomes—yet the pace of new signals suggests the field is still finding actionable leads. The window is still open.